Warning Letter — NuScience Peptides LLC
The FDA issued a warning letter to NuScience Peptides LLC following an evaluation by the Center for Drug Evaluation and Research (CDER). The source indicates that the enforcement action is related to compliance issues managed by CDER.
NuScience Peptides LLC, their regulatory and quality departments, and companies marketing peptide products that may be classified as drugs.
The involvement of CDER suggests that the products in question are being regulated as drugs, likely due to their intended use or manufacturing standards. This action indicates a focus on unapproved drug products or violations of cGMP, which can lead to significant operational disruptions, including potential product seizures or injunctions if the identified deficiencies are not remediated. The source provides limited detail on specific product names or violations, but the issuance of a formal warning letter signifies that the FDA considers the firm's previous responses or current practices to be insufficient.
Review all digital and physical marketing materials for therapeutic claims that could cause a product to be classified as an unapproved new drug. Verify that manufacturing processes and facilities meet current Good Manufacturing Practice (cGMP) standards for drug products. Ensure all marketed drug products have undergone the required FDA approval process.
FDA Warning Letter issued to: NuScience Peptides LLC. 08/24/2026 — Center for Drug Evaluation and Research (CDER). Source: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/nuscience-peptides-llc-733652-08242026
Open in openFDA / FDA.gov